Shire Uses Foresight to Expand in Ophthalmology
This article was originally published in Scrip
Executive Summary
Shire PLC has acquired privately held Foresight Biotherapeutics for $300m, gaining FST-100, a Phase III-ready drug in development for infectious conjunctivitis and a commercial complement to Shire's lifitegrast pending at FDA.